Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Mitigating effect of clopidogrel and systematic management on adverse events after interventional therapy for coronary heart disease

Jing Shao¹ , Wenqiang Chen²

¹Jinan Third People's Hospital, China; ²Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China.

For correspondence:- Jing Shao Email: lanzongyilangnpkk@163.com Tel:+13805310270

Accepted: 20 January 2022 Published: 28 February 2021

Citation: Shao J, Chen W. Mitigating effect of clopidogrel and systematic management on adverse events after interventional therapy for coronary heart disease. Trop J Pharm Res 2022; 21(2):387-392 doi: 10.4314/tjpr.v21i2.23

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the efficacy of clopidogrel combined with systemic management care in the prevention of adverse events in patients with coronary heart disease after interventional therapy.

Methods: 100 patients undergoing interventional therapy after coronary heart disease admitted to Jinan Third People’s Hospital from April 2018 to April 2020 were assigned at a ratio of 1:1 either into control (low-molecular-weight heparin (LMWH) injection) or study groups randomly (clopidogrel plus system management care). Thrombin time, prothrombin time, fibrinogen, incidence of adverse events, NIHSS score and QLI score were determined for the two groups.

Results: There thrombin time, prothrombin time and fibrinogen in the two groups were similar (p > 0.05). The study group showed a significantly lower incidence of adverse events than the control group (p < 0.05). The treatment administered to the study group resulted in a higher QLI (quality of life) scores than those in the control group (p < 0.05). Remarkably lower National Institutes of Health Stroke Scale (NIHSS) score was reported in the study group versus control group (p < 0.05).

Conclusion: Clopidogrel plus systemic management care might be a preferable therapeutic strategy for patients with coronary heart disease undergoing interventional therapy. It reduces the incidence of adverse events, significantly improves the quality of life of patients, and enhances neurological function. Thus, this therapeutic strategy has significant promise in the management of coronary heart disease.

Keywords: Coronary heart disease, Interventional therapy, Clopidogrel, Systemic management care, Adverse events